The Potential Role of Selected miRNA in Uveal Melanoma Primary Tumors as Early Biomarkers of Disease Progression.


Journal

Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097

Informations de publication

Date de publication:
02 03 2020
Historique:
received: 31 01 2020
revised: 27 02 2020
accepted: 27 02 2020
entrez: 6 3 2020
pubmed: 7 3 2020
medline: 30 1 2021
Statut: epublish

Résumé

Uveal melanoma (UM) is the most common primary tumor of the eye diagnosed in adults, associated with a high risk of metastasis and thereby, poor prognosis. Among known risk factors for the development of metastatic disease is the loss of BAP1 expression and chromosome 3 monosomy in the primary tumor. However, the expression levels of specific micro RNAs (miRNA) in tumor tissue may also serve as a valuable marker for determining the risk of metastatic disease in patients with primary uveal melanoma. In our study, we analyzed the miRNA expression data of cases selected from The Cancer Genome Atlas study on uveal melanoma, and determined a panel of 15 miRNAs differentially expressed between patients with primary and metastatic disease. Next, 6 miRNAs were validated on a group of 46 tumor samples from primary and metastatic patients. We have shown, that expression of hsa-miR-592, hsa-miR-346, and hsa-miR-1247 was significantly increased, while hsa-miR-506 and hsa-miR-513c were decreased in the tumors of patients with metastatic disease. Hsa-miR-196b expression did not differ between the two subgroups, however, we showed significant correlation with BAP1 expression. Moreover, hsa-miR-592 also showed correlation with monosomy 3 tumors. Gene ontology analysis revealed involvement of those miRNAs with cellular processes mediating the metastatic process. Our results showed that miRNAs play an important role in the deregulation of several oncogenic pathways in UM and can, thereby, promote metastatic spread to distant organs. Moreover, differentially expressed miRNAs may be used as an interesting biomarker for the assessment of metastatic risk in uveal melanoma patients.

Identifiants

pubmed: 32131485
pii: genes11030271
doi: 10.3390/genes11030271
pmc: PMC7140886
pii:
doi:

Substances chimiques

BAP1 protein, human 0
Biomarkers, Tumor 0
MIRN1247 microRNA, human 0
MIRN346 microRNA, human 0
MIRN506 microRNA, human 0
MIRN513A1 microRNA, human 0
MIRN592 microRNA, human 0
MicroRNAs 0
Tumor Suppressor Proteins 0
Ubiquitin Thiolesterase EC 3.4.19.12

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Nat Cell Biol. 2018 Oct;20(10):1181-1192
pubmed: 30202049
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
BMC Cancer. 2009 Nov 18;9:401
pubmed: 19922656
Prog Retin Eye Res. 2011 Sep;30(5):285-95
pubmed: 21658465
Int J Oncol. 2015 Nov;47(5):1963-70
pubmed: 26398880
Oncol Res. 2018 Aug 23;26(7):1073-1081
pubmed: 29295726
Nat Struct Mol Biol. 2009 Feb;16(2):144-50
pubmed: 19182800
Am J Pathol. 2015 Sep;185(9):2412-20
pubmed: 26362716
Clin Cancer Res. 2017 Sep 1;23(17):5255-5266
pubmed: 28533224
Ophthalmology. 2018 Feb;125(2):203-209
pubmed: 28823399
JAMA Ophthalmol. 2020 Jan 2;:
pubmed: 31895446
Oncol Rep. 2017 Jan;37(1):297-304
pubmed: 28004116
Cancer Biomark. 2017 Dec 6;20(4):589-596
pubmed: 28800318
N Engl J Med. 2010 Dec 2;363(23):2191-9
pubmed: 21083380
Oncol Lett. 2017 Sep;14(3):3255-3260
pubmed: 28927074
Invest Ophthalmol Vis Sci. 2014 Jun 26;55(8):5160-7
pubmed: 24970262
Oncol Rep. 2017 Dec;38(6):3447-3454
pubmed: 29039599
Oncotarget. 2017 Apr 18;8(16):26600-26612
pubmed: 28460450
Mol Med Rep. 2015 Sep;12(3):4403-4409
pubmed: 26063413
Biol Res. 2018 May 24;51(1):13
pubmed: 29793538
J Biosci. 2019 Dec;44(6):
pubmed: 31894107
Oncogene. 2012 Mar 22;31(12):1558-70
pubmed: 21860416
Cancer Cell. 2017 Aug 14;32(2):204-220.e15
pubmed: 28810145
Nat Methods. 2015 Aug;12(8):697
pubmed: 26226356
Oncotarget. 2016 Mar 22;7(12):13742-53
pubmed: 26885612
Biomed Res Int. 2017;2017:6361420
pubmed: 29159179
Int J Exp Pathol. 2018 Aug;99(4):199-205
pubmed: 30175411
J Cell Biochem. 2018 Nov;119(11):8773-8783
pubmed: 30076753
Cancers (Basel). 2019 Oct 19;11(10):
pubmed: 31635116
Cancers (Basel). 2019 Jun 12;11(6):
pubmed: 31212861
Exp Eye Res. 2019 Mar;180:242-249
pubmed: 30615885
Am J Transl Res. 2018 Oct 15;10(10):3122-3132
pubmed: 30416655
Sci Rep. 2018 Oct 31;8(1):16138
pubmed: 30382159
Onco Targets Ther. 2019 Dec 18;12:11231-11239
pubmed: 31908489
Biomed Pharmacother. 2015 Feb;69:214-20
pubmed: 25661360
Life Sci. 2020 Mar 1;244:117300
pubmed: 31953162
Mol Med Rep. 2019 Apr;19(4):2599-2610
pubmed: 30816460
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Nucleic Acids Res. 2020 Jan 8;48(D1):D127-D131
pubmed: 31504780
J Cancer. 2017 Aug 21;8(13):2643-2652
pubmed: 28900502
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
J Biochem Mol Toxicol. 2016 Dec;30(12):602-607
pubmed: 27501413
Nucleic Acids Res. 2016 Jan 8;44(1):e3
pubmed: 26271990
Melanoma Res. 2008 Jun;18(3):184-90
pubmed: 18477892
Clin Ophthalmol. 2017 Jan 31;11:279-289
pubmed: 28203054
Science. 2010 Dec 3;330(6009):1410-3
pubmed: 21051595
Oncol Rep. 2017 Jul;38(1):343-351
pubmed: 28586038
DNA Cell Biol. 2017 Oct;36(10):837-844
pubmed: 28749709
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W169-73
pubmed: 23680784
Curr Mol Med. 2014 Mar;14(3):316-27
pubmed: 24588767
Elife. 2015 Aug 12;4:
pubmed: 26267216
Gene. 2017 Feb 5;600:21-28
pubmed: 27913185

Auteurs

Joanna Patrycja Wróblewska (JP)

Department of Oncologic Pathology and Prophylaxis, Poznan University of Medical Sciences, Garbary 15, 61-866 Poznan, Poland.
Department of Tumor Pathology, Greater Poland Cancer Centre, Garbary 15, 61-866 Poznan, Poland.

Michał Stefan Lach (MS)

Radiobiology Lab, Department of Medical Physics, Greater Poland Cancer, Garbary 15, 61-866 Poznan, Poland.
Department of Electroradiology, Poznan University of Medical Sciences, Garbary 15, 61-866 Poznan, Poland.

Adam Ustaszewski (A)

Institute of Human Genetics, Polish Academy of Sciences, Strzeszynska 32, 60-479 Poznan, Poland.

Katarzyna Kulcenty (K)

Radiobiology Lab, Department of Medical Physics, Greater Poland Cancer, Garbary 15, 61-866 Poznan, Poland.
Department of Electroradiology, Poznan University of Medical Sciences, Garbary 15, 61-866 Poznan, Poland.

Matthew Ibbs (M)

Department of Oncologic Pathology and Prophylaxis, Poznan University of Medical Sciences, Garbary 15, 61-866 Poznan, Poland.
Department of Tumor Pathology, Greater Poland Cancer Centre, Garbary 15, 61-866 Poznan, Poland.

Inga Jagiełło (I)

Department of Tumor Pathology, Greater Poland Cancer Centre, Garbary 15, 61-866 Poznan, Poland.

Wiktoria Maria Suchorska (WM)

Radiobiology Lab, Department of Medical Physics, Greater Poland Cancer, Garbary 15, 61-866 Poznan, Poland.
Department of Electroradiology, Poznan University of Medical Sciences, Garbary 15, 61-866 Poznan, Poland.

Andrzej Marszałek (A)

Department of Oncologic Pathology and Prophylaxis, Poznan University of Medical Sciences, Garbary 15, 61-866 Poznan, Poland.
Department of Tumor Pathology, Greater Poland Cancer Centre, Garbary 15, 61-866 Poznan, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH